BIOSANTE PHARM (NASDAQ:BPAX)

1.57

0.03 (1.88%)

BIOSANTE PHARM (NASDAQ:BPAX) Delayed :
Previous Close	$1.60	52 Week High	$2.70
Open	$1.63	52 Week Low	$0.81
Day High	$1.63	P/E	N/A
Day Low	$1.55	EPS	$-0.60
Volume	129,058
More BPAX Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker	# Stories	Ticker	# Stories
CEGE	8	NTES	2
TSEM	2	HRS	2
ISIL	2	LDK	2
GIL	1	BRCM	1
SBLK	1	HILL	1
ELX	1	TCX	1

View All Entities

Aug 13, 2009 08:58 AM BioSante (BPAX) Higher After Positive Phase III Data on LibiGel

Nov 9, 2009 11:25 AM Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
Oct 20, 2009 08:36 AM BioSante (BPAX) Gets Green Light to Continue LibiGel Study
Oct 15, 2009 09:45 AM Oppenheimer Resumes Coverage on BioSante Pharmaceuticals (BPAX) with an Outperform
Sep 30, 2009 04:21 PM BioSante Pharmaceuticals (BPAX) and Cell Genesys (CEGE) Announce Approval of Merger by BioSante Stockholders
Sep 23, 2009 08:02 AM BioSante Pharmaceuticals (BPAX) and Cell Genesys (CEGE) Announce Final Exchange Ratio for Merger

Nov 17, 2009 08:00AM BioSante Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
Nov 16, 2009 12:30PM BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
Nov 10, 2009 08:00AM BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
Nov 9, 2009 04:25PM BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results
Oct 29, 2009 08:00AM BioSante Pharmaceuticals to Present at the Oppenheimer Health Care Conference

Nov 16, 2009 02:38 AM Developments for Parkinson's Disease Ignite Investor Enthusiasm
Nov 9, 2009 11:25 AM Analyst upgrades, downgrades and initiations: ANF, AZN, BX, GPS, PH, RAIL, VRSN ...
Oct 21, 2009 05:09 AM Transformative Times for BioSante Pharmaceuticals
Oct 20, 2009 11:36 AM BioMed News Bytes: Angiotech, BioSante, HGSI
Oct 16, 2009 05:48 AM October FDA Calendar Stocks: Tricks or Treats?

Nov 9, 2009 04:38PM Form 10-Q BIOSANTE PHARMACEUTICALS For: Sep 30
Nov 9, 2009 04:34PM Form 8-K BIOSANTE PHARMACEUTICALS For: Nov 09
Oct 26, 2009 05:19PM Form SC 13G BIOSANTE PHARMACEUTICALS Filed by: TANG CAPITAL PARTNERS LP
Oct 15, 2009 07:28PM Form 4 SHERWIN STEPHEN A For: Oct 14
Oct 15, 2009 07:00PM Form 4 POTTS JOHN T JR For: Oct 14

Scott Ferguson
on Jul 1, 2009
at 02:43 AM Merger or Fleece It appears that CEGE got all their ducks in order on June 23, 2009. We were told that the firm had approx 36 million in cash and that the OS was approx 109 million. Each common share would have a value of approx .33 cents per. One week later the BOD announces a merger with BPAX!!!! One week later!. It is a stock deal valued at 38 million in BPAX stock. What a joke...it appears that the only winners are a few left at the top . Is it true that Dr. SHERWIN will receive about 5 million USD dollars? WHY?. This is not a merger it is a take under. Cege was working on Cancer and Parkinson's.....why did we partner with a firm that has zero relevant data. The deal is very poor for CEGE Shareholders. The two firms have a lock up penalty of One million if this does not happen. Something is very wrong with this deal. Regards, Scott Ferguson
Article: BioSante (BPAX) and Cell Genesys (CEGE) Agree to Merge; Deal Valued at $38M
Diwakar Rai
on May 7, 2009
at 02:26 AM No matter of my interest I am interested to work in the field of drug delivery systems to enhance the cellular uptake of drugs in side the cells. But inthis regard, i could not recieve any type of such matter on your home page.
Article: BioSante Pharmaceuticals (BPAX) Reaches Agreement with FDA Under Special Protocol Assessment for LibiGel

No comments are currently available.